$0.81
-0.04 (-5.08%)
Open$0.86
Previous Close$0.86
Day High$0.87
Day Low$0.80
52W High$1.45
52W Low$0.70
Volume—
Avg Volume230.6K
Market Cap38.52M
P/E Ratio—
EPS$-0.32
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+4,514.3% upside
Current
$0.81
$0.81
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 1.51M | 3.79M | 3.81M |
| Net Income | -15,002,699 | 783.4K | 928.9K |
| Profit Margin | -994.5% | 20.7% | 24.4% |
| EBITDA | -15,572,242 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |